Pulmonary hypertension (pHTN) is one of the complications of mitral valve surgery for mitral regurgitation and is often associated with an increased risk of mortality. However, for patients undergoing transcatheter mitral valve repair (TMVr), the association of pHTN with the clinical outcomes of the treatment are not well studies. This study aims to examine the association between pHTN and the incidence of heart failure and all-cause mortality after TMVr.
This retrospective cohort study included a total of 4,071 patients who underwent TMVr. The patients were divided into two groups based on their invasive mean pulmonary arterial pressure (mPAP). The four groups were as follows: no pHTN (mPAP <25 mm Hg, n=1,103), mild pHTN (mPAP 25-34 mm Hg, n=1,399), moderate pHTN (mPAP 35-44 mm Hg, n=1,011), and severe pHTN (mPAP ≥45 mm Hg, n=558). The primary outcome was readmissions for heart failure and mortality.
The rate of readmission for heart failure was 33.6%, which was highest in the severe pHTN group (45.2%) and the lowest in the no pHTN group (27.8%). 1-year mortality was also the highest in the severe pHTN group (27.8%) and the lowest in the no pHTN group (16.3%).
The research concluded that higher pulmonary hypertension in patients who underwent TMVr was associated with an increased risk of readmission for heart failure and 1-year mortality.